A phase II trial of pembrolizumab and poly-ICLC in patients with metastatic mismatch repair-proficient colon cancer.

Nabin Raj Karki,Kulsum Bano,Sadek Ramses,Asha Nayak

A phase II trial of pembrolizumab and poly-ICLC in patients with metastatic mismatch repair-proficient colon cancer.

2021

Nabin Raj Karki
Kulsum Bano
Sadek Ramses
Asha Nayak

e15552Background: Single agent programmed cell death protein 1 (PD1) inhibitor is ineffective against mismatch repair proficient (MMRp) colon cancer with response rates in single digits. Polyinosin...

Keywords:

Medicine
DNA mismatch repair
Pembrolizumab
in patient
Colorectal cancer
single agent
Cancer research
Poly ICLC
Programmed cell death 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations